The LIFT-ECHO Last Mile Project
NCT07094308 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2026-03-12
Summary
This is a multi-site research study to evaluate the efficacy and effectiveness of the LIFT-ECHO program to improve clinical outcomes in patients and improve patient reported quality of life (PRQOL). LIFT-ECHO (Learn Intestinal Failure Tele-ECHO) is a tele-health learning program whereby non-specialist clinicians meet with and learn from CIF specialist teams with the goal of improving the knowledge of CIF. LIFT-ECHO sessions consist of group discussion of anonymized real-world patient cases, followed by a didactic presentation from an expert in intestinal failure. Sessions are held twice a month and last 60-90 minutes. The study will proceed in three distinct phases, correlating with Project Aims. During phase 1 (Aim 1), an intestinal failure disease activity index (IF-DAI) will be developed as a measure of short- to medium-term clinical activity in CIF patients; this phase will be undertaken through Delphi Rounds. During Phase 2 (corresponding to project Aim 2), the researchers will evaluate the impact of physician participation in LIFT-ECHO on patients with CIF on PN. Lastly, Phase 3, corresponding to Aim 3 will be the dissemination of LIFT-ECHO nationally. For Phase 2, the researchers had originally proposed that patients and physicians will be recruited from the records of Optum Home Infusion services. Patient reported quality of life and clinical status will be assessed using surveys at baseline. Physicians will then be invited to participate in a module of LIFT-ECHO consisting of 8 one- hour-long sessions held over the course of 2-4 months. Patients will then be followed for 12 months to assess if physician participation in LIFT-ECHO improves patient reported quality of life and/or treatment efficacy and effectiveness. The main procedures for physician participants in the study include: completion of baseline and monthly surveys, possible participation in an appreciative inquiry workshop and possible participation in a focus group discussion, optional, but encouraged, participation in LIFT-ECHO. The main procedures for patient participants include: completion of surveys at baseline, participation in 12 monthly follow-up phone calls with a study team member. The proposed trial has a total length of 34 months.
Conditions
- Intestinal Failure
Interventions
- BEHAVIORAL
-
Learn Intestinal Failure Tele-ECHO Program
LIFT-ECHO (Learn Intestinal Failure Tele-ECHO) is a virtual tele-education program designed to improve the knowledge and clinical decision-making of non-specialist clinicians managing patients with chronic intestinal failure (CIF) on parenteral nutrition (PN). The intervention consists of eight 60-90-minute sessions delivered over 2-4 months. Each session includes the presentation of anonymized real-world CIF cases and a didactic lecture by an expert in intestinal rehabilitation. Participating physicians may also complete baseline and follow-up surveys, and optionally participate in focus groups or appreciative inquiry workshops.
- BEHAVIORAL
-
Standard of Care
Participants will receive routine clinical care for chronic intestinal failure from their usual providers. No additional educational programming or intervention is delivered during this period.
Sponsors & Collaborators
-
Rhode Island Hospital
collaborator OTHER -
The New York Academy of Medicine
collaborator OTHER - collaborator OTHER
-
London School of Economics and Political Science
collaborator OTHER -
Icahn School of Medicine at Mount Sinai
lead OTHER
Principal Investigators
-
Kishore Iyer, MD · Icahn School of Medicine at Mount Sinai
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 5 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-07-01
- Primary Completion
- 2030-06-30
- Completion
- 2030-06-30
Countries
- United States
- United Kingdom
Study Locations
More Related Trials
-
Fecal Microbiota Transplantation for Decompensated Cirrhosis
NCT03014505 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of Cilofexor in Adults With Primary Sclerosing Cholangitis
NCT03890120 ·Status: TERMINATED ·Phase: PHASE3
-
Rifaximin in Fatty Liver Disease
NCT01355575 ·Status: TERMINATED ·Phase: PHASE4
-
A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
NCT06461208 ·Status: RECRUITING ·Phase: PHASE3
-
Clinical Research of Tapering UDCA in PBC Patients With a Complete Response
NCT04650243 ·Status: RECRUITING ·Phase: PHASE4
-
Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease
NCT05754385 ·Status: COMPLETED ·Phase: NA
-
Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy
NCT04155099 ·Status: TERMINATED ·Phase: PHASE2
-
The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT04465032 ·Status: UNKNOWN ·Phase: PHASE4
-
Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
NCT02457637 ·Status: COMPLETED
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
NCT03394924 ·Status: COMPLETED ·Phase: PHASE2
-
Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis
NCT03803540 ·Status: UNKNOWN ·Phase: PHASE1
-
Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
NCT01963845 ·Status: COMPLETED ·Phase: PHASE2
-
Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
NCT01315795 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
NCT03421431 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Long-term Peg Intron vs. Colchicine in Non-responders.
NCT00179413 ·Status: COMPLETED ·Phase: PHASE4
-
Pentoxifylline for Primary Biliary Cirrhosis
NCT01249092 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis
NCT06306781 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
NCT03468140 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Octreotide in Severe Polycystic Liver Disease
NCT00426153 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
NCT05036031 ·Status: UNKNOWN
-
Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response
NCT03590886 ·Status: COMPLETED
-
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
NCT03957070 ·Status: COMPLETED ·Phase: NA
-
Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis
NCT05863364 ·Status: RECRUITING ·Phase: NA
-
A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
NCT05293938 ·Status: WITHDRAWN
-
Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)
NCT07216859 ·Status: NOT_YET_RECRUITING ·Phase: NA